China's Surgical Robots vs Intuitive Surgical's da Vinci: Toumai, Tinavi & the Price Gap

The two Chinese fronts: laparoscopy and orthopedics

Chinese surgical robotics competes on two fronts. In laparoscopic (abdominal/pelvic) surgery, the direct da Vinci competitor is MicroPort MedBot's Toumai (图迈) — the first Chinese multi-arm laparoscopic system to win NMPA approval (commercial launch January 2022), which by early 2026 had won 200+ global orders, led Chinese-brand laparoscopic sales, and was adopted by six of China's top-100 hospitals. Jingfeng Medical (精锋医疗) runs a multi-port plus single-port platform with 184.8% revenue growth in 2025, and Cornerstone Robotics offers the Sentire platform. In orthopedics, Tinavi (天智航) — the listed pioneer of Chinese surgical robotics — holds roughly 40% of China's orthopedic-robot market with its TiRobot line.

The price gap that changes procurement

The ~40–60% price difference is decisive in China's tender-driven hospital market, where public procurement increasingly favors domestic equipment and steep tariffs raise the cost of foreign imports. Intuitive still holds ~42% of China's minimally-invasive surgical robot market by some 2025 estimates (~198 da Vinci units across 72 tertiary hospitals), but every new tender is contested.

Where da Vinci still wins

The price gap does not mean parity. Intuitive's moat is not hardware — it is clinical evidence depth (8M+ procedures, a vast instrument ecosystem, surgeon training programs and long-term outcome data) and regulatory penetration worldwide. Chinese systems have shorter track records, a narrower range of specialty instruments, and limited outside-China regulatory clearances. They win on cost and domestic policy; da Vinci wins on proven outcomes and global trust. The realistic near-term trajectory is not takeover but a two-tier market: Chinese systems scale across Chinese and emerging-market hospitals on price; da Vinci defends premium academic and Western markets on evidence.

What to watch

• Single-port systems: Toumai's single-port laparoscopic system (NMPA-approved in urology, general surgery and gynecology in 2025) directly matches da Vinci SP's headline feature — watch cadence.
• Overseas clearances: whether MicroPort MedBot and Jingfeng win CE/FDA clearance, which would turn a domestic price story into a global one.
• Procedure volume per system: da Vinci averages ~326 cases/unit/year in China vs ~248 industry average; utilization, not installed base, decides the winner.

Frequently asked questions

Can Chinese surgical robots compete with da Vinci?

Yes in tenders and price: MicroPort MedBot's Toumai has won 200+ global orders and leads Chinese-brand laparoscopic sales; Tinavi's TiRobot holds about 40% of China's orthopedic-robot market. They typically cost 40–60% less than da Vinci.

How much cheaper is a Chinese surgical robot than da Vinci?

Chinese multi-arm laparoscopic systems like Toumai cost roughly $400,000–$600,000 and orthopedic robots like TiRobot $350,000–$500,000, versus about $1.5M–$2.5M for a da Vinci system.

Does Intuitive still dominate China?

Intuitive still leads overall (~42% of China's minimally-invasive surgical robot market in 2025, ~198 da Vinci units across 72 tertiary hospitals), but Chinese brands are winning domestic tenders and tariffs favor local procurement.

Who are the leading Chinese surgical robot companies?

MicroPort MedBot (Toumai, HK-listed), Tinavi (TiRobot orthopedic), Jingfeng Medical (multi- and single-port laparoscopic, 184.8% revenue growth in 2025), and Cornerstone Robotics (Sentire).